文献速递神经肿瘤

转化生长因子β诱导蛋白(TGFBI)是间质型高级别胶质瘤的潜在特征基因

Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma.
PubMed 文献 · J Neurooncol · 2018-01-02

研究整合七个GEO数据集、TCGA和REMBRANDT数据库,分析TGFBI表达与胶质瘤病理分级、分子分型及预后的关系。结果显示TGFBI表达与病理分级正相关,在胶质瘤中显著高于正常脑组织,在间质型高级别胶质瘤中显著高于前神经型,高表达组生存期显著缩短。TGFBI可能是间质型高级别胶质瘤的潜在特征基因和预后分子。

要点

  • TGFBI表达水平与胶质瘤病理分级呈正相关。
  • TGFBI在间质型高级别胶质瘤中的表达显著高于前神经型。
  • TGFBI高表达组GBM患者生存期显著短于低表达组。

核心结论

  • TGFBI表达与胶质瘤病理分级正相关,可能是间质型高级别胶质瘤的潜在特征基因和潜在预后分子。

研究设计与样本

  • 研究下载并分析七个GEO数据集(GSE68848、GSE4290、GSE13041、GSE4271、GSE83300、GSE34824和GSE84010)、TCGA数据库和REMBRANDT数据库的数据,探讨TGFBI是否可作为胶质瘤的生物标志物。

主要发现

  • 在微阵列数据(GSE68848、GSE4290)和RNA-seq数据(TCGA)中,TGFBI表达水平与病理分级呈正相关,且胶质瘤中TGFBI表达水平显著高于正常脑组织。
  • 在GSE13041、GSE4271和TCGA队列中,间质型高级别胶质瘤的TGFBI表达显著高于前神经型。
  • 对GSE83300数据集、REMBRANDT和TCGA队列中GBM患者的Kaplan-Meier生存分析显示,TGFBI表达前50%组患者的生存期明显短于后50%组。
  • 对III级胶质瘤的分析显示,TGFBI高表达组的中位生存时间显著短于TGFBI低表达组。
  • TGFBI表达水平可能与胶质瘤的若干经典分子特征相关,如IDH突变、TP53突变、EGFR扩增等。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Previous study revealed that higher expression of transforming growth factor beta induced (TGFBI) is correlated to poorer cancer-specific survival and higher proportion of tumor necrosis and Fuhrman grades III and IV in clear cell renal cell carcinomas. However, the relationships between TGFBI expression and malignant phenotypes of gliomas remain unclear. We downloaded and analyzed data from seven GEO datasets (GSE68848, GSE4290, GSE13041, GSE4271, GSE83300, GSE34824 and GSE84010), the TCGA database and the REMBRANDT database to investigate whether TGFBI could be a biomarker of glioma. From microarray data (GSE68848, GSE4290) and RNA-seq data (TCGA), TGFBI expression levels were observed to correlate positively with pathological grade, and TGFBI expression levels were significantly higher in gliomas than in normal brain tissues. Furthermore, in GSE13041, GSE4271 and the TCGA cohort, TGFBI expression in the mesenchymal (Mes) subtype high-grade glioma (HGG) was significantly higher than that in the proneural subtype. Kaplan-Meier survival analysis of GBM patients in the GSE83300 dataset, REMBRANDT and TCGA cohort revealed that patients in the top 50% TGFBI expression group survived for markedly shorter periods than those in the bottom 50%. Analysis of grade III gliomas showed that the median survival time was significantly shorter in the TGFBI high expression group than in the TGFBI low expression group. In addition, we found that TGFBI expression levels might relate to several classical molecular characterizations of glioma, such as, IDH mutation, TP53 mutation, EGFR amplification, etc. These results suggest that TGFBI expression positively correlates with glioma pathological grades and that TGFBI is a potential signature gene for Mes subtype HGG and a potential prognostic molecule.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Pan YB, Zhang CH, Wang SQ, et al. Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma. J Neurooncol. 2018. PMID: 29294230. doi:10.1007/s11060-017-2729-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。